Top

CNS Drugs

Published in:

01-09-2009 | Adis Drug Profile

Asenapine

Authors: Juliane Weber, Paul L. McCormack

Published in: CNS Drugs | Issue 9/2009

Abstract

▴ Asenapine is a novel psychopharmacological agent that binds with high affinity and specificity to numerous dopamine, serotonin, noradrenaline (norepinephrine) and histamine receptor subtypes. It is being developed for the treatment of schizophrenia and bipolar mania.
▴ In two randomized, controlled trials of asenapine monotherapy and in one randomized, controlled trial of adjunctive asenapine therapy in adult patients with bipolar I disorder, sublingual asenapine produced significantly greater reductions from baseline than placebo in clinician-assessed Young Mania Rating Scale (YMRS) total score at 3 weeks.
▴ In two randomized, controlled trials in adult patients with acute schizophrenia, treatment with asenapine reduced from baseline the clinician-assessed Positive and Negative Syndrome Scale (PANSS) total score to a significantly greater extent than placebo at 6 weeks.
▴ In schizophrenic patients with predominant, persistent, negative symptoms, asenapine at 26 weeks reduced the Negative Symptom Assessment (NSA-16) total score from baseline to an extent similar to that observed with olanzapine.
▴ Sublingual asenapine was generally well tolerated in clinical trials, with most treatment-emergent adverse events being of mild to moderate severity. Incidence rates of clinically significant weight gain, extrapyramidal symptoms, hyperprolactinaemia and alterations in glucose or lipid metabolism were generally low.

Ayuso-Mateos JL. Global burden of bipolar disorder in the year 2000 [online]. Available from URL: http://www.who.int/healthinfo/statistics/bod_bipolar.pdf [Accessed 2009 Mar 9]

Ayuso-Mateos JL. Global burden of schizophrenia in the year 2000: version 1 estimates [online]. Available from URL: http://www.who.int/healthinfo/statistics/bod_schizophrenia.pdf [Accessed 2009 Mar 9]

Schering-Plough Corporation. US FDA issues complete response letter for Saphris™ (asenapine) in the acute treatment of both schizophrenia and bipolar I disorder [media release]. 2009 Jan 14

Freedman R. The choice of antipsychotic drugs for schizophrenia. N Engl J Med 2005 Sep 22; 353(12): 1286–8PubMedCrossRef

Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353(12): 1209–23PubMedCrossRef

Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20(5): 389–409PubMedCrossRef

Revicki DA, Matza LS, Flood E, et al. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics 2005; 23(6): 583–94PubMedCrossRef

Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008; 26(2): 149–62PubMedCrossRef

Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009 Jan; 23(1): 65–73PubMedCrossRef

10.

Tarazi FI, Moran-Gates T, Wong EH, et al. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol. Epub 2008 Aug 21

11.

Huang M, Li Z, Dai J, et al. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 2008 Nov; 33(12): 2934–45PubMedCrossRef

12.

Tarazi FI, Moran-Gates T, Wong EH, et al. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl) 2008 May; 198(1): 103–11CrossRef

13.

Franberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008 Feb; 196(3): 417–29CrossRef

14.

Andree B, Halldin C, Vrijmoed-de Vries M, et al. Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology (Berl) 1997 Jun 11; 131: 339–45CrossRef

15.

Ghanbari R, El Mansari M, Shahid M, et al. Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, α₂-adrenergic and D₂ receptors in the rat brain. Eur Neuropsychopharmacol 2009 Mar; 19(3): 177–87PubMedCrossRef

16.

Franberg O, Marcus MM, Ivanov V, et al. Asenapine elevates cortical dopamine, noradrenaline and serotonin release: evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) 2009 Jun; 204(2): 251–64CrossRef

17.

Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008; 68(16): 2269–92PubMedCrossRef

18.

Potkin SG, Alva G, Panagides J, et al. Predicting clinical antipsychotic doses from preclinical and PET studies: a case study with asenapine [abstract plus poster]. American College of Neuropsychopharmacology 42nd Annual Meeting; 2003 Dec 7–11; Puerto Rico

19.

Henry B, Grimwood S, de Greef HJMM, et al. Asenapine: a translational analysis of receptor occupancy in human and rat brain with therapeutic implications [abstract no. NR5-030]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DC

20.

Sumner BEH, Shahid M, Tarazi FI, et al. Asenapine displays distinctive induction patterns of c-fos mRNA expression in rat forebrain regions. Neuropsychopharmacology 2006 Dec; 31 Suppl. 1: 196–7

21.

Tarazi FI, Choi YK, Gardner M, et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009 May; 63(5): 413–20PubMedCrossRef

22.

Gerrits M, Doorstam DP, Spaans E, et al. Effect of valproate on the glucuronidation of asenapine [abstract no. PI-68]. Clin Pharmacol Ther 2008 Mar; 83Suppl. 1: S29

23.

Dogterom P, Schnabel PG, Timmer C, et al. Effect of carbamazepine on asenapine pharmacokinetics [abstract no. PII-44]. Clin Pharmacol Ther 2008 Mar; 83Suppl. 1: S55

24.

Hulskotte E, Spaans E, Timmer C, et al. Effects of water intake and smoking on the absorption of sublingually administered asenapine [abstract no. NR1-040]. 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16–21; San Francisco (CA)

25.

Dogterom P, Hulskotte E, Gerrits M, et al. Asenapine pharmacokinetics: influence of cytochrome p450 modulators and udp-glucuronyltransferase inhibition [abstract no. P.3.d.008]. Eur Neuropsychopharmacol 2008 Oct; 18Suppl. 4: S452–3CrossRef

26.

Peeters P, Bockbrader H, Spaans E, et al. Asenapine pharmacokinetics: influence of hepatic and renal impairment [abstract no. NR4-081]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DC

27.

Calabrese JR, Cohen M, Zhao J, et al. Efficacy and safety of asenapine adjunctive treatment for acute mania associated with bipolar disorder [abstract no. NR3-061]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DC

28.

Panagides J, McIntyre RS, Alphs L, et al. Asenapine in acute mania: a randomized, double-blind, placebo- and olanzapine-controlled trial (ARES 7501004) [abstract no. 720]. Biol Psychiatry 2007 Apr 15; 61 Suppl. 8: 222S-3S

29.

Hirschfeld RMA, Panagides J, Alphs L, et al. Asenapine in acute mania: a randomized, double-blind, placebo- and olanzapine-controlled trial (ARES 7501005) [abstract no. NR333]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19–24; San Diego (CA)

30.

McIntyre R, Cohen M, Zhao J, et al. Double-blind extension studies of asenapine in patients with bipolar mania [abstract no. NR4-092]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DC

31.

Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007 Oct; 68(10): 1492–500PubMedCrossRef

32.

Kane JM, Zhao J, Cohen M, et al. Efficacy and safety of asenapine in patients with acute schizophrenia [abstract no. NR4-051]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DC

33.

Cazorla P, Panagides J, Alphs L, et al. Asenapine versus olanzapine in patients with predominant, persistent negative symptoms of schizophrenia [abstract no. NR4-082]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DC

34.

Cazorla P, Phiri P, den Hollander W, et al. Long-term treatment with asenapine versus olanzapine in subjects with predominant, persistent negative symptoms of schizophrenia [abstract no. 088]. 47th Annual Meeting of the American College of Neuropsychopharmacology; 2008 Dec7–11;Scottsdale(AZ)

35.

Panagides J, McIntyre RS, Alphs L, et al. Asenapine versus olanzapine in acute mania: a double-blind extension study (ARES 7501006) [abstract no. 721]. Biol Psychiatry 2007 Apr 15; 61 Suppl. 8: 223S

36.

van Willigenburg A, Zhao J, Panagides J. Asenapine effects on individual young mania rating scale items in bipolar disorder patients: a pooled analysis [abstract no. NR4-007]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DC

37.

Cazorla P, Panagides J, Alphs L, et al. Asenapine versus olanzapine in patients with predominant persistent negative symptoms of schizophrenia [abstract no. P-02.26]. Int J Neuropsychopharmacol 2008 Jul; 11 Suppl. 1: 138–9

38.

Alphs L, Panagides J, Lancaster S. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale. Psychopharmacol Bull 2007; 40(2): 41–53PubMed

39.

ClinicalTrials.gov. 6-Month extension trial of asenapine with olanzapine in negative symptom patients who completed the first 6-month trial (A7501014) (completed) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00174265?term=asenapine+olanzapine+schizophrenia&rank=3 [Accessed 2009 Aug 2]

40.

Emsley RA, Schoemaker JH, Vrijland P, et al. Long-term safety of asenapine versus olanzapine in patients with schizophrenia or schizoaffective disorder [abstract no. 323]. 21st Annual US Psychiatric and Mental Health Congress; 2008 Oct 30–Nov 1; San Diego (CA)

41.

Preskorn S, Chapel S, Panagides J. Effect of asenapine versus quetiapine and placebo on QTc interval in patients with schizophrenia [abstract no. P.3.c.050]. Eur Neuropsychopharmacol 2007 Oct; 17Suppl. 4: S453CrossRef

42.

Potkin SG, Kane JM, Emsley RA, et al. Asenapine in schizophrenia: an overview of clinical trials in the Olympia program [abstract no. 78]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DC

43.

McIntyre R, Panagides J, Alphs L, et al. Treatment of mania in bipolar I disorder: a placebo- and olanzapine-controlled trial of asenapine (ARES 7501005) [abstract no. P.2.e.012]. Eur Neuropsychopharmacol 2007 Oct; 17Suppl. 4: S383CrossRef

44.

Schering-Plough Corporation. Schering-Plough announces European filing of Sycrest® (asenapine) for the treatment of schizophrenia and bipolar I disorder [media release]. 2009 Jun 2

Title: Asenapine
Authors: Juliane Weber
Paul L. McCormack
Publication date: 01-09-2009
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 9/2009
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/11200860-000000000-00000

2024 ASCO Annual Meeting

Springer Medicine

Asenapine

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2009

Aripiprazole

The Effect of Migraine Prophylaxis on Migraine-Related Resource Use and Productivity

Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions

Armodafinil

Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression

Tumour Necrosis Factor Modulation for Treatment of Alzheimer’s Disease